Walleye Capital LLC Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Walleye Capital LLC boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 955.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 141,171 shares of the company’s stock after purchasing an additional 127,800 shares during the quarter. Walleye Capital LLC’s holdings in IDEAYA Biosciences were worth $4,472,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. KBC Group NV increased its stake in shares of IDEAYA Biosciences by 29.1% during the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock valued at $72,000 after acquiring an additional 513 shares during the last quarter. Amalgamated Bank boosted its position in shares of IDEAYA Biosciences by 22.9% in the third quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock worth $90,000 after acquiring an additional 530 shares during the last quarter. US Bancorp DE grew its holdings in IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after purchasing an additional 689 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in IDEAYA Biosciences by 35.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock worth $94,000 after purchasing an additional 796 shares during the last quarter. Finally, Allworth Financial LP raised its stake in IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 800 shares during the period. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $27.36 on Monday. The firm has a 50-day moving average of $29.53 and a two-hundred day moving average of $35.23. The stock has a market cap of $2.36 billion, a P/E ratio of -11.74 and a beta of 0.86. IDEAYA Biosciences, Inc. has a 1-year low of $25.20 and a 1-year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period in the previous year, the company posted ($0.46) earnings per share. As a group, equities analysts expect that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on IDYA shares. Oppenheimer restated an “outperform” rating and set a $53.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Citigroup cut their price objective on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. UBS Group initiated coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.